Search Results - "Jarugula, V"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase by Darpo, B, Benson, C, Dota, C, Ferber, G, Garnett, C, Green, CL, Jarugula, V, Johannesen, L, Keirns, J, Krudys, K, Liu, J, Ortemann-Renon, C, Riley, S, Sarapa, N, Smith, B, Stoltz, RR, Zhou, M, Stockbridge, N

    Published in Clinical pharmacology and therapeutics (01-04-2015)
    “…The QT effects of five “QT‐positive” and one negative drug were tested to evaluate whether exposure–response analysis can detect QT effects in a small study…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects by He, Y-L, Paladini, S, Sabia, H, Campestrini, J, Zhang, Y, Leon, S, Ligueros-Saylan, M, Jarugula, V

    “…To assess the bioequivalence of vildagliptin/metformin fixed-dose combination tablets (at doses of 50/500, 50/850 and 50/1,000 mg) with free combination of the…”
    Get full text
    Journal Article
  4. 4

    Labeling of drugs that interact with oral contraceptives by Kim, M., Castillo, E., Jarugula, V. R., Parekh, A., Furlong, L. A., Hunt, J. P., Malinowski, H. J.

    Published in Clinical pharmacology and therapeutics (01-02-2005)
    “…Background Labeling should clearly describe drug‐drug interactions (DDI) between oral contraceptives (OCs) and other drugs. The purpose of this study was to…”
    Get full text
    Journal Article
  5. 5

    Nonlinear pharmacokinetics of 5-fluorouracil in rats by Jarugula, V R, Lam, S S, Boudinot, F D

    Published in Journal of pharmaceutical sciences (01-06-1997)
    “…The effects of dose on the pharmacokinetics of 5-fluorouracil (5-FU) were investigated following intravenous administration of 5-FU at 10, 50, and 100 mg/kg to…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Pharmacokinetics of 5-carboranyl-2'-deoxyuridine in rats by Jarugula, V R, Schinazi, R F, Fulcrand, G, el Kattan, Y, Liotta, D C, Boudinot, F D

    Published in Journal of pharmaceutical sciences (01-12-1994)
    “…The pharmacokinetics of 5-carboranyl-2'-deoxyuridine (CDU) after intravenous administration of 25 mg/kg was investigated in rats. The uptake of CDU into brain…”
    Get more information
    Journal Article
  8. 8
  9. 9

    PIII-49 by Kim, M., Park, J., Ortiz, S., Jarugula, V. R., Parekh, A.

    Published in Clinical pharmacology and therapeutics (01-02-2006)
    “…BACKGROUND The risk of thromboembolic events in women using hormonal contraceptive products is a concern. Doses of ethinyl estradiol (EE) have been…”
    Get full text
    Journal Article
  10. 10

    Experience evaluating QT prolongation data by Kenna, L. A., Parekh, A., Jarugula, V., Chatterjee, D. J., Sun, H., Kim, M. J., Ortiz, S., Hunt, J. P., Malinowski, H.

    Published in Clinical pharmacology and therapeutics (01-02-2004)
    “…A preliminary concept paper (http://cdernet.cder.fda.gov/QTWG/QT%20Workshop/qt4jam.pdf) advises on the design of effective QT assessment studies. We aimed to…”
    Get full text
    Journal Article
  11. 11

    High-performance liquid chromatographic determination of 5-fluorouracil and its prodrugs, tegafur and 4-deoxy-5-fluorouracil, in rat plasma by Jarugula, Venkateswar R., Douglas Boudinot, F.

    “…A rapid, sensitive and reproducible ion-pair, reversed-phase high-performance liquid chromatographic (HPLC) method was developed to simultaneously quantitate…”
    Get full text
    Journal Article